The initial public offering (IPO) of Advanced Enzymes has been fully subscribed. While on day one the issue had been subscribed 0.89 times, on Thursday the response was even better with the issue being oversubscribed 4.27 times. Till 5pm on Thursday, bids had been received for 1.38 crore shares of the 32.34 lakh shares on offer priced in a band of `880-896 per share.
Qualified institutional buyers (QIBs) bid for 54.21 lakh shares of the 9.18 lakh shares reserved for them, an oversubscription of more than five times.
High net worth individuals (HNIs) bid for 5.7 lakh shares of the 6.86 lakh shares reserved for them, bidding for just 0.83 times of their quota. The retail portion was oversubscribed by nearly five times with investors bidding for 78 lakh shares of the 16.2 lakh shares offered for them. Employees, who were offered a discount of `86 per share bid for 1,040 of the total 25,188 shares offered to them.
On Tuesday the company allotted 13.71 lakh shares aggregating `122.85 crore to anchor investors including D B International, Kuwait Investment Authority Fund, DSP BlackRock, HDFC Trustee, ICICI Prudential, Reliance Capital, Birla Sunlife, IDFC among others.
The enzyme manufacturer reported a net profit of `78.43 crore in FY16 and a total revenue of `294.6 crore. Healthcare and nutrition and bio-processing business of the company constitute 87.62% and 12.38% of its total revenues, respectively.